Literature DB >> 23176755

Vigilance decrement during the on-the-road driving tests: the importance of time-on-task in psychopharmacological research.

Joris C Verster1, Thomas Roth.   

Abstract

Time dependent decrements in performance are characteristic of activities that are monotonous and require focused attention for an extended period of time. A vigilance task is a task that participants can perform without difficulty for a short period of time, but with time their performance becomes impaired. A real world example of such a vigilance task is prolonged highway driving. The on-the-road driving test in normal traffic was specifically designed to measure the effects of vigilance decrement associated with driving. The primary parameter of this test is the Standard Deviation of Lateral Position (SDLP), i.e. the weaving of the car. This methodological paper explains the typical vigilance decrement seen in the on-the-road driving test and discusses the importance of sufficient time-on-task to elucidate potential adverse drug effects on driving. Performance decrements (SDLP increment) as a function of time are seen after both drug and placebo treatment, following a similar pattern over distance/time traveled. However, whereas for some drugs SDLP differences between drug and placebo are constant, other drugs produce additional performance decrement that increases over distance traveled. It is concluded that driving tests of short duration (e.g. less than half an hour) may fail to detect drug-related impairment, because participants are capable of, at least in part, counteracting the impairment by increased effort and motivation to perform the test.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Driving; Impairment; SDLP; Vigilance decrement

Mesh:

Substances:

Year:  2012        PMID: 23176755     DOI: 10.1016/j.aap.2012.10.005

Source DB:  PubMed          Journal:  Accid Anal Prev        ISSN: 0001-4575


  8 in total

1.  Lapses of attention as outcome measure of the on-the-road driving test.

Authors:  Joris C Verster; Adriana C Bervoets; Suzanne de Klerk; Thomas Roth
Journal:  Psychopharmacology (Berl)       Date:  2013-08-24       Impact factor: 4.530

2.  Insomnia and driving ability.

Authors:  Joris C Verster; Thomas Roth
Journal:  Sleep       Date:  2014-09-01       Impact factor: 5.849

3.  Hangover research needs: proceedings of the 5th Alcohol Hangover Research Group meeting.

Authors:  Joris C Verster; Chris Alford; Adriana C Bervoets; Suzanne de Klerk; James A Grange; Anna Hogewoning; Kate Jones; Darren L Kruisselbrink; Lauren Owen; Thomas M Piasecki; Senta Jorinde Raasveld; Sam Royle; Wendy S Slutske; Gordon S Smith; Richard Stephens
Journal:  Curr Drug Abuse Rev       Date:  2013-09

4.  Modafinil improves real driving performance in patients with hypersomnia: a randomized double-blind placebo-controlled crossover clinical trial.

Authors:  Pierre Philip; Cyril Chaufton; Jacques Taillard; Aurore Capelli; Olivier Coste; Damien Léger; Nicholas Moore; Patricia Sagaspe
Journal:  Sleep       Date:  2014-03-01       Impact factor: 5.849

5.  Effects of alcohol on automated and controlled driving performances.

Authors:  Catherine Berthelon; Guy Gineyt
Journal:  Psychopharmacology (Berl)       Date:  2013-11-30       Impact factor: 4.530

6.  Time-on-Task Effect During Sleep Deprivation in Healthy Young Adults Is Modulated by Dopamine Transporter Genotype.

Authors:  Brieann C Satterfield; Jonathan P Wisor; Michelle A Schmidt; Hans P A Van Dongen
Journal:  Sleep       Date:  2017-12-01       Impact factor: 5.849

7.  A psychology of the human brain-gut-microbiome axis.

Authors:  Andrew P Allen; Timothy G Dinan; Gerard Clarke; John F Cryan
Journal:  Soc Personal Psychol Compass       Date:  2017-04-18

8.  An explorative approach to understanding individual differences in driving performance and neurocognition in long-term benzodiazepine users.

Authors:  Frederick R J Vinckenbosch; Annemiek Vermeeren; Eric F P M Vuurman; Nick N J J M van der Sluiszen; Joris C Verster; Aurora J A E van de Loo; Joke H van Dijken; Janet L Veldstra; Karel A Brookhuis; Dick De Waard; Johannes G Ramaekers
Journal:  Hum Psychopharmacol       Date:  2021-02-06       Impact factor: 1.672

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.